Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Starpharma in Nanotechnology (SPHRY)

No earlier versions found for this Subject.

Return to Starpharma in Nanotechnology (SPHRY)

This small company has received strong financial suppor for its research Starpharma Holdings Limited (USOTC: SPHRY; ASX: SPL) today signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to fund a clinical trial to test the use of VivaGel(TM) in the prevention of genital herpes. Genital herpes is the second indication for which VivaGel(TM)
is being developed.
This latest support from the NIH is in addition to a previously announced US$20.3 (A$26m) million funding provided by the NIH to support the development of VivaGel(TM) for the prevention of HIV. In both cases funding is non- dilutive for shareholders and has no negative impact on the commercial returns that Starpharma will receive from VivaGel(TM).
The reaction on it stockprice is remarcable but obviously not noted by Silicon Investors but worth to be discussed. Fred